Bluejay Diagnostics Inc (BJDX)
Sector • Healthcare Industry • Medical Equipment & Supplies |
Industry • Medical Equipment & Supplies |
Sector • Healthcare |
BJDX, contraction in the corporate behavior throughout the financial fourth quarter of 2022
Bluejay Diagnostics Inc recorded fourth quarter of 2022 operating loss of $-2.453612 millions
Published Mar 21 2023
CSIMarket Team / CSIMarket.com
As the October to December 31 2022 reporting season resumes, many corporations have disclosed the earnings. Some of them, are multiple constituents of the Medical Equipment & Supplies sector. As well as, now, BJDX announced operating shortfall of $-2.453612 millions, for the fiscal three months closing Dec 31 2022.
In the recent approaching stage of the company, the stakeholders await for new revenue sources to come as early as possible. They are less interested in the prevailing operational behavior of the Bluejay Diagnostics Inc .
The crucial observation in financial interval closing December 31 2022, next to the deficiency in top-line, is a $-2.386 millions net loss, which has expanded notably from $-1.193 millions, compared to the corresponding period a year before.
Bluejay Diagnostics Inc is expected to report next financial results on May 08, 2023.
In the recent approaching stage of the company, the stakeholders await for new revenue sources to come as early as possible. They are less interested in the prevailing operational behavior of the Bluejay Diagnostics Inc .
The crucial observation in financial interval closing December 31 2022, next to the deficiency in top-line, is a $-2.386 millions net loss, which has expanded notably from $-1.193 millions, compared to the corresponding period a year before.
Bluejay Diagnostics Inc is expected to report next financial results on May 08, 2023.